Total submissions: 3
Submitter | RCV | SCV | Clinical significance | Condition | Last evaluated | Review status | Method | Comment |
---|---|---|---|---|---|---|---|---|
Clinical Cancer Genomics Laboratory, |
RCV001528196 | SCV001739437 | likely pathogenic | Breast-ovarian cancer, familial, susceptibility to, 1 | 2021-01-01 | criteria provided, single submitter | clinical testing | |
Labcorp Genetics |
RCV001873732 | SCV002179712 | pathogenic | Hereditary breast ovarian cancer syndrome | 2021-04-09 | criteria provided, single submitter | clinical testing | For these reasons, this variant has been classified as Pathogenic. This sequence change creates a premature translational stop signal (p.Asn1121*) in the BRCA1 gene. It is expected to result in an absent or disrupted protein product. Loss-of-function variants in BRCA1 are known to be pathogenic (PMID: 20104584). This variant is not present in population databases (ExAC no frequency). This variant has not been reported in the literature in individuals with BRCA1-related conditions. |
Ambry Genetics | RCV002324127 | SCV002607183 | pathogenic | Hereditary cancer-predisposing syndrome | 2020-09-17 | criteria provided, single submitter | clinical testing | The c.3359_3360insG pathogenic mutation, located in coding exon 9 of the BRCA1 gene, results from an insertion of one nucleotide at position 3359, causing a translational frameshift with a predicted alternate stop codon (p.N1121*). This alteration is expected to result in loss of function by premature protein truncation or nonsense-mediated mRNA decay. As such, this alteration is interpreted as a disease-causing mutation. |